Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle

Biochimie

Volumn 108, Issue , 2015, Pages 94-100

  Koroleva, Olga N ^b   Pham, The Hien ^a   Bouvier, Dominique ^a   Dufau, Laure ^a   Qin, Lixian ^a   Reboud Ravaux, Michèle ^a   Ivanov, Alexander A ^c   Zhuze, Alexei L ^c   Gromova, Elizaveta S ^b   Bouvier Durand, Michelle ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b MOSCOW STATE UNIVERSITY   (Russian Federation)

^c ENGELHARDT INSTITUTE OF MOLECULAR BIOLOGY   (Russian Federation)

Author keywords

Bisbenzimidazole derivatives; Constitutive proteasome; Immunoproteasome; In silico docking; Specific inhibitors of the trypsin like sites

Indexed keywords

CALPAIN 1; CATHEPSIN B; DIMERIC BISBENZIMIDAZOLE; MONOMERIC BISBENZIMIDAZOLE; PIBENZIMOL; PROTEASOME; PROTEASOME INHIBITOR; TRYPSIN; UNCLASSIFIED DRUG; CALPAIN; ISOENZYME;

ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG SPECIFICITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR MODEL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME ACTIVE SITE; HELA CELL LINE; IMMUNOLOGY; METABOLISM; MOUSE;

ANIMALS; BISBENZIMIDAZOLE; CALPAIN; CATALYTIC DOMAIN; CATHEPSIN B; HELA CELLS; HUMANS; ISOENZYMES; MICE; MOLECULAR DOCKING SIMULATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; TRYPSIN;

EID: 84912553367     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2014.11.002     Document Type: Article

References (60)

1. J. Adams, V.J. Palombella, E.A. Sausville, J. Johnson, A. Destree, D.D. Lazarus, J. Maas, C.S. Pien, S. Prakash, and P.J. Elliott Proteasome inhibitors: a novel class of potent and effective antitumor agents Cancer Res. 59 1999 2615 2622
2. A.F. Kisselev, and A.L. Goldberg Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 8 2001 739 758
3. A.F. Kisselev, W.A. van der Linden, and H.S. Overkleeft Proteasome inhibitors: an expanding army attacking a unique target Chem. Biol. 19 2012 99 115
4. E. Genin, M. Reboud-Ravaux, and J. Vidal Proteasome inhibitors: recent advances and new perspectives in medicinal chemistry Curr. Top. Med. Chem. 10 2010 232 256
5. M.A. Grawert, and M. Groll Exploiting nature's rich source of proteasome inhibitors as starting points in drug development Chem. Commun. (Cambridge, U. K.) 48 2012 1364 1378
6. M.L. Stein, and M. Groll Applied techniques for mining natural proteasome inhibitors Biochim. Biophys. Acta 1843 2014 26 38
7. A. Rentsch, D. Landsberg, T. Brodmann, L. Bülow, A.K. Girbig, and M. Kalesse Synthesis and pharmacology of proteasome inhibitors Angew. Chem. Int. Ed. Engl. 52 2013 5450 5488
8. O. Coux, K. Tanaka, and A.L. Goldberg Structure and functions of the 20S and 26S proteasomes Annu. Rev. Biochem. 65 1996 801 847
9. A. Hershko, and A. Ciechanover The ubiquitin system Annu. Rev. Biochem. 67 1998 425 479
10. L. Borissenko, and M. Groll 20S proteasome and its inhibitors: crystallographic knowledge for drug development Chem. Rev. 107 2007 687 717
11. A.J. Marques, R. Palanimurugan, A.C. Matias, P.C. Ramos, and R. Dohmen Catalytic mechanism and assembly of the proteasome Chem. Rev. 109 2009 1509 1536
12. A.M. Weissman, N. Shabek, and A. Ciechanover The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation Nat. Rev. Mol. Cell Biol. 12 2011 605 620
13. R.C. Kane, A.T. Farrell, R. Sridhara, and R. Pazdur United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy Clin. Cancer Res. 12 2006 2955 2960
14. R.C. Kane, R. Dagher, A. Farrell, C.W. Ko, R. Sridhara, R. Justice, and R. Pazdur Bortezomib for the treatment of mantle cell lymphoma Clin. Cancer Res. 13 2007 5291 5294
15. P. Lawasut, D. Chauhan, J. Laubach, C. Hayes, C. Fabre, M. Maglio, C. Mitsiades, T. Hideshima, K.C. Anderson, and P.G. Richardson New proteasome inhibitors in myeloma Curr. Hematol. Malig. Rep. 7 2012 258 266
16. R. Piva, B. Ruggeri, M. Williams, G. Costa, I. Tamagno, D. Ferrero, V. Giai, M. Coscia, S. Peola, M. Massaia, G. Pezzoni, C. Allievi, N. Pescalli, M. Cassin, S. di Giovine, P. Nicoli, P. de Feudis, I. Strepponi, I. Roato, R. Ferracini, B. Bussolati, G. Camussi, S. Jones-Bolin, K. Hunter, H. Zhao, A. Neri, A. Palumbo, C. Berkers, H. Ovaa, A. Bernareggi, and G. Inghirami CEP-18770: a novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood 111 2008 2765 2775
17. E. Kupperman, E.C. Lee, Y. Cao, B. Bannerman, M. Fitzgerald, A. Berger, J. Yu, Y. Yang, P. Hales, F. Bruzzese, J. Liu, J. Blank, K. Garcia, C. Tsu, L. Dick, P. Fleming, L. Yu, M. Manfredi, M. Rolfe, and J. Bolen Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res. 70 2010 1970 1980
18. H.J. Zhou, M.A. Aujay, M.K. Bennett, M. Dajee, S.D. Demo, Y. Fang, M.N. Ho, J. Jiang, C.J. Kirk, G.J. Laidig, E.R. Lewis, Y. Lu, T. Muchamuel, F. Parlati, E. Ring, K.D. Shenk, J. Shields, P.J. Shwonek, T. Stanton, C.M. Sun, C. Sylvain, T.M. Woo, and J. Yang Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 52 2009 3028 3038
19. A.M. Roccaro, A. Sacco, M. Aujay, H.T. Ngo, A.K. Azab, F. Azab, P. Quang, P. Maiso, J. Runnels, K.C. Anderson, S. Demo, and I.M. Ghobrial Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia Blood 115 2010 4051 4060
20. D. Chauhan, A.V. Singh, M. Aujay, C.J. Kirk, M. Bandi, B. Ciccarelli, N. Raje, P. Richardson, and K.C. Anderson A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma Blood 116 2010 4906 4915
21. V.R. Macherla, S.S. Mitchell, R.R. Manam, K.A. Reed, T.H. Chao, B. Nicholson, G. Deyanat-Yadzi, B. Mai, P.R. Jensen, W.F. Fenical, S.T.C. Neuteboom, K.S. Lam, M.A. Palladino, and B.C.M. Potts Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor J. Med. Chem. 48 2005 3684 3687
22. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, A. Letai, H. Ovaa, C. Berkers, B. Nicholson, T.H. Chao, S.T. Neuteboom, P. Richardson, M.A. Palladino, and K.C. Anderson A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib Cancer Cell 8 2005 407 419
23. A. Hovhannisyan, T.H. Pham, D. Bouvier, A. Piroyan, L. Dufau, L. Qin, Y. Cheng, G. Melikyan, M. Reboud-Ravaux, and M. Bouvier-Durand New C4- and C1-derivatives of furo[3,4-c]pyridine-3-ones and related compounds: evidence for site-specific inhibition of the constitutive proteasome and its immunoisoform Bioorg. Med. Chem. Lett. 24 2014 1571 1580
24. P.P. Geuring, W.A. van der Linden, A.C. Mirabella, N. Gallastegui, G. de Bruin, A.E. Blom, M.J. Voges, E.D. Mock, B.I. Florea, G.A. van der Marel, C. Driessen, M. van der Stelt, H.S. Overkleeft, and A.F. Kisselev Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites J. Med. Chem. 56 2013 1262 1275
25. N. Gallastegui, P. Beck, M. Arciniega, R. Huber, S. Hillebrand, and M. Groll Hydroxyureas as non-covalent proteasome inhibitors Angew. Chem. Int. Ed. 51 2012 247 249
26. X. Maréchal, E. Genin, L. Qin, O. Sperandio, M. Montes, N. Basse, N. Richy, M.A. Miteva, M. Reboud-Ravaux, J. Vidal, and B.O. Villoutreix 1,2,4-Oxadiazoles identified by virtual screening and their non-covalent inhibition of the human 20S proteasome Curr. Med. Chem. 20 2013 2351 2362
27. M. Groll, M. Goetz, M. Kaiser, E. Weyher, and L. Moroder TMC-95 based inhibitor design provides evidence for the catalytic versatility of the proteasome Chem. Biol. 13 2006 607 614
28. C. Blackburn, K.M. Gigstad, P. Hales, K. Garcia, M. Jones, F.J. Bruzzese, C. Barrett, J.X. Liu, T.A. Soucy, D.S. Sappal, N. Bump, E.J. Olhava, P. Fleming, L.R. Dick, C. Tsu, M.D. Sintchak, and J.L. Blank Characterization of a new series of non-covalent inhibitors with exquisite potency and selectivity for the 20S β5-subunit Biochem. J. 430 2010 461 476
29. M. Groll, N. Gallastegui, X. Maréchal, V. Le Ravalec, N. Basse, N. Richy, E. Genin, R. Huber, L. Moroder, J. Vidal, and M. Reboud-Ravaux 20S proteasome inhibition: designing non-covalent linear peptide mimics of the natural product TMC-95A ChemMedChem 4 2010 1701 1705
30. A. Desvergne, E. Genin, X. Maréchal, N. Gallastegui, L. Dufau, N. Richy, M. Groll, J. Vidal, and M. Reboud-Ravaux Dimerized linear mimics of a natural cyclopeptide (TMC-95A) are potent non-covalent inhibitors of the eukaryotic 20S proteasome J. Med. Chem. 56 2013 3367 3378
31. J. Kaffy, G. Bernadat, and S. Ongeri Non-covalent proteasome inhibitors Curr. Pharm. Des. 19 2012 4115 4130
32. T.H. Pham, A. Hovhannisyan, D. Bouvier, L. Tian, M. Reboud-Ravaux, G. Melikyan, and M. Bouvier-Durand A new series of N5 derivatives of the 1,1,5-trimethyl furo[3,4-c]pyridine-3,4-dione (cerpegin) selectively inhibits the post-acid activity of mammalian 20S proteasomes Bioorg. Med. Chem. Lett. 22 2012 3822 3827
33. A. Hovhannisyan, T.H. Pham, D. Bouvier, L.X. Qin, G. Melikyan, M. Reboud-Ravaux, and M. Bouvier-Durand C1 and N5 derivatives of cerpegin: synthesis of a new series based on structure-activity relationships to optimize their inhibitory effect on 20S proteasome Bioorg. Med. Chem. Lett. 23 2013 2696 2703
34. Y. Koguchi, J. Kohno, M. Nishio, K. Takahashi, T. Okuda, T. Ohnuki, and S. Komatsubara TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei sacc. TC 1093. Taxonomy, production, isolation, and biological activities J. Antibiot. 53 2000 105 109
35. I. Nickeleit, S. Zender, F. Sasse, R. Geffers, G. Brandes, I. Sörensen, H. Steinmetz, S. Kubicka, T. Carlomagno, D. Menche, I. Gütgemann, J. Buer, A. Gossler, M.P. Manns, M. Kalesse, R. Frank, and N.P. Malek Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition Cancer Cell 14 2008 23 35
36. P.M. Kloetzel Antigen processing by the proteasome Nat. Rev. Mol. Cell Biol. 2 2001 179 187
37. M. Groettrup, C.J. Kirk, and M. Basler Proteasomes in immune cells: more than peptide producers? Nat. Rev. Immunol. 10 2010 73 78
38. E.M. Huber, M. Basler, R. Schwab, W. Heinemayer, C.J. Kirk, M. Groettrup, and M. Groll Immuno- and constitutive proteasome crystal structures reveal differences in substrate and inhibitor specificity Cell 148 2012 727 738
39. D.J. Kuhn, S.A. Hunsucker, Q. Chen, P.M. Voorhees, M. Orlowski, and R.Z. Orlowski Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors Blood 113 2009 4667 4676
40. M. Wehenkel, J.O. Ban, Y.K. Ho, K.C. Carmony, J.T. Hong, and K.B. Kim A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice Br. J. Cancer 107 2012 53 62
41. F. Parlati, S.J. Lee, M. Aujay, E. Suzuki, K. Levitsky, J.B. Lorens, D.R. Micklem, P. Ruurs, C. Sylvain, Y. Lu, K.D. Shenk, and M.K. Bennett Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome Blood 114 2009 3439 3447
42. A.V. Singh, M. Bandi, M.A. Aujay, C.J. Kirk, D.E. Hark, N. Raje, D. Chauhan, and K.C. Anderson PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo Br. J. Haematol. 152 2011 155 163
43. N.A. Cherepanova, A.A. Ivanov, D.V. Maltseva, A.S. Minero, A.V. Gromyko, S.A. Streltsov, A.L. Zhuze, and E.S. Gromova Dimeric bisbenzimidazoles inhibit the DNA methylation catalyzed by the murine Dnmt3a catalytic domain J. Enzyme Inhib. Med. Chem. 26 2011 295 300
44. M.V. Darii, A.R. Rakhimova, V.N. Tashlitsky, S.V. Kostyuk, N.N. Veiko, A.A. Ivanov, A.L. Zhuze, and E.S. Gromova Dimeric bisbenzimidazoles: cytotoxicity and effects on DNA methylation in normal and cancer human cells Mol. Biol. 47 2013 259 266
45. O.Y. Susova, A.A. Ivanov, S.S. Morales Ruiz, E.A. Lesovaya, A.V. Gromyko, S.A. Streltsov, and A.L. Zhuze Minor groove dimeric bisbenzimidazoles inhibit in vitro DNA binding to eukaryotic DNA topoisomerase I Biochemistry (Moscow) 75 2010 695 701
46. S.P. Korolev, V.N. Tashlitskii, M.A. Smolov, A.V. Gromyko, A.L. Zhuze, Y.Y. Agapkina, and M.B. Gottikh HIV-1 integrase inhibition by dimeric bisbenzimidazoles with different spacer structures Mol. Biol. 44 2010 633 641
47. V.L. Tunitskaya, A.V. Mukovnya, A.A. Ivanov, A.V. Gromyko, A.V. Ivanov, S.A. Streltsov, A.L. Zhuze, and S.N. Kochetkov Inhibition of the helicase activity of the HCV NS3 protein by symmetrical dimeric bis-benzimidazoles Bioorg. Med. Chem. Lett. 21 2011 5331 5335
48. M. Tonelli, B. Tasso, L. Mina, G. Paglietti, V. Boido, and F. Sparatore Primary anti-proliferative activity evaluation of 1-(quinolizidin-1′-yl)methyl- and 1-(tert-amino)alkyl-substituted 2-phenyl-, 2-benzyl- and 2-[(benzotriazol-1/2-yl)methyl] benzimidazoles on human cancer cell lines Mol. Diversity 17 2013 409 419
49. K. Paul, S. Bindal, and V. Luxami Synthesis of new conjugated coumarin-benzimidazole hybrids and their anticancer activity Bioorg. Med. Chem. Lett. 23 2013 3667 3672
50. P. Xiang, T. Zhou, L. Wang, C.Y. Sun, J. Hu, Y.L. Zhao, and L. Yang Novel benzothiazole, benzimidazole and benzoxazole derivatives as potential antitumor agents: synthesis and preliminary in vitro biological evaluation Molecules 17 2012 873 883
51. B.S. Sekhon Exploiting the power of stereochemistry in drugs: an overview of racemic and enantiopure drugs J. Mod. Med. Chem. 1 1 2013 10 36
52. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov, and P.E. Bourne The protein data bank Nucleic Acids Res. 28 2000 235 242
53. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 31 2010 455 461
54. W. Humphrey, A. Dalke, and K.J. Schulten VMD: visual molecular dynamics J. Mol. Graphics 14 1996 33 38
55. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, M.N. Ho, J. Jiang, G.J. Laidig, E.R. Lewis, F. Parlati, K.D. Shenk, M.S. Smyth, C.M. Sun, M.K. Vallone, T.M. Woo, C.J. Molineaux, and M.K. Bennett Antitumor activity of PR-171, a novel irreversible inhibitor of proteasome Cancer Res. 67 2007 6383 6391
56. T. Muchamuel, M. Basler, M.A. Aujay, E. Suzuki, K.W. Kalim, C. Lauer, C. Sylvain, E.R. Ring, J. Shields, J. Jiang, P. Shwonek, F. Parlati, S.D. Demo, M.K. Bennett, C.J. Kirk, and M. Groettrup A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis Nat. Med. 15 2009 781 787
57. S.A. Streltsov, A.V. Gromyko, V.A. Oleinikov, and A.L. Zhuze The Hoechst 33258 covalent dimer covers a total turn of the double-stranded DNA J. Biomol. Struct. Dyn. 24 2006 285 302
58. B.M. Kessler, D. Tortorella, M. Altun, A.F. Kisselev, E. Fiebiger, B.G. Hekking, H.L. Ploegh, and H.S. Overkleeft Extended peptide-based inhibitors efficiently target the proteasome and reveal overlapping specificities of the catalytic beta-subunits Chem. Biol. 8 2001 913 929
59. C. Zhuang, Z. Miao, Y. Wu, Z. Guo, J. Li, J. Yao, C. Xing, C. Sheng, and W. Zhang Double-edged swords as cancer therapeutics: novel, orally active, small molecules simultaneously inhibit p53-MDM2 interaction and the NF-kB pathway J. Med. Chem. 57 2014 567 577
60. T.S. Gujral, L. Peshkin, and M.W. Kirschner Exploiting polypharmacology for drug target deconvolution Proc. Natl. Acad. Sci. U. S. A. 111 2014 5048 5053